4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 785.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,337.50p
  • 52 Week Low: 703.85p
  • Currency: UK Pounds
  • Shares Issued: 15.54m
  • Volume: 19
  • Market Cap: £121.98m
  • Beta: 0.03

Latest ShareCast News

4basebio partner starts dosing patients in opDNA-based trial

By Josh White

Date: Monday 27 Oct 2025

(Sharecast News) - 4basebio said on Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial using an mRNA therapy developed with the company's proprietary 'opDNA' synthetic DNA template, marking what it called a major milestone for the technology's adoption in advanced genetic medicines.

4basebio reports strong full-year progress

By Josh White

Date: Tuesday 27 May 2025

(Sharecast News) - 4basebio reported strong progress for the year ended 31 December on Tuesday, with revenue doubling from DNA sales to £0.93m and key operational milestones achieved.

4basebio's Cambridge facility gets GMP certification

By Josh White

Date: Wednesday 02 Apr 2025

(Sharecast News) - 4basebio announced on Wednesday that it has received Good Manufacturing Practice (GMP) certification from the UK's Medicines and Healthcare Products Regulatory Agency for its DNA manufacturing facility in Cambridge, marking a key milestone in its development as a supplier of clinical-grade synthetic DNA.

4basebio losses widen as it progresses commercia... 27-Sep-2024 ShareCast
4basebio to provide synthetic DNA to tier-one ph... 10-Apr-2024 ShareCast
4basebio client gets approval to start trial in ... 21-Mar-2024 ShareCast
4basebio inks significant DNA supply contract 01-Mar-2024 ShareCast
First-half losses narrow for 4basebio 21-Sep-2023 ShareCast
4basebio inks supply deal with Italy's Neomatrix 25-May-2023 ShareCast
4basebio enters neurofibromatosis collaboration ... 10-Jun-2022 ShareCast
Losses to continue as 4basebio focuses on commer... 09-May-2022 ShareCast
4basebio inks development deal with Heqet Therap... 27-Apr-2022 ShareCast
4basebio launches two new synthetic DNA products 23-Mar-2022 ShareCast
4basebio makes progress with manufacturing devel... 15-Feb-2022 ShareCast
4basebio enters research collaboration with eThe... 18-Jan-2022 ShareCast
4basebio enters development deal with T-cell the... 23-Nov-2021 ShareCast
4basebio files for patent on novel DNA type 22-Jun-2021 ShareCast
 
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 785.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,337.50p
52 Week Low 703.85p
Volume 19
Shares Issued 15.54m
Market Cap £121.98m
Beta 0.03

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average
12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average
Price Trend
34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average
4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average
Income Not Available
Growth
59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average
65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average

4basebio Dividends

No dividends found

Trades for 05-Nov-2025

Time Volume / Share Price
16:01 9 @ 753.50p
15:56 10 @ 753.50p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page